Content deleted Content added
Anypodetos (talk | contribs) →top: New ATC code |
no longer a stub |
||
| (8 intermediate revisions by 6 users not shown) | |||
Line 1:
{{Short description|Chemical compound}}
{{Use American English|date=February 2021}}
{{Use dmy dates|date=February 2021}}
{{Infobox drug
| image = Trilaciclib.svg
| width =
Line 15 ⟶ 13:
| Drugs.com = {{drugs.com|pro|Cosela}}
| MedlinePlus =
| DailyMedID = Trilaciclib
| pregnancy_
| pregnancy_
| pregnancy_category=
| routes_of_administration = [[Intravenous]]
| class = [[CDK inhibitor|Cyclin-dependent kinase (CDK) inhibitor]]
| ATC_prefix = V03
| ATC_suffix = AF12
Line 102 ⟶ 95:
}}
'''Trilaciclib''', sold under the brand name '''Cosela''', is a [[medication]] used to reduce the frequency of chemotherapy-induced bone marrow suppression.<ref name="Cosela FDA label" /><ref name="FDA PR">{{cite press release | title=FDA Approves Drug to Reduce Bone Marrow Suppression Caused by Chemotherapy | website=U.S. [[Food and Drug Administration]] (FDA) | date=12 February 2021 | url=https://www.fda.gov/news-events/press-announcements/fda-approves-drug-reduce-bone-marrow-suppression-caused-chemotherapy | access-date=12 February 2021}} {{PD-notice}}</ref><ref>{{cite press release | title=FDA Approves G1 Therapeutics' Cosela (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression | publisher=G1 Therapeutics | via=GlobeNewswire | date=12 February 2021 | url=https://www.globenewswire.com/news-release/2021/02/13/2175184/0/en/FDA-Approves-G1-Therapeutics-COSELA-trilaciclib-The-First-and-Only-Myeloprotection-Therapy-to-Decrease-the-Incidence-of-Chemotherapy-Induced-Myelosuppression.html | access-date=12 February 2021}}</ref><ref name="Dhillon_2021">{{cite journal | vauthors = Dhillon S | title = Trilaciclib: First Approval | journal = Drugs | volume = 81 | issue = 7 | pages = 867–874 | date = May 2021 | pmid = 33861388 | doi = 10.1007/s40265-021-01508-y | s2cid = 233258487 }}</ref>
The most common side effects include fatigue; low levels of calcium, potassium and phosphate; increased levels of an enzyme called aspartate aminotransferase; headache; and infection in the lungs (pneumonia).<ref name="FDA PR" />
Trilaciclib may help protect bone marrow cells from damage caused by chemotherapy by inhibiting [[cyclin-dependent kinase]] 4/6, a type of enzyme.<ref name="FDA PR" /> Trilaciclib is the first therapy in its class and was approved for medical use in the United States in February 2021.<ref name="FDA PR"/><ref>{{cite web | title=Drug Approval Package: Cosela | website=U.S. [[Food and Drug Administration]] (FDA) | date=12 March 2021 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214200Orig1s000TOC.cfm | access-date=13 September 2021}}</ref> The U.S. [[Food and Drug Administration]] considers it to be a [[first-in-class medication]].<ref name="New Drug Therapy Approvals 2021">{{cite report | title=Advancing Health Through Innovation: New Drug Therapy Approvals 2021 | website=U.S. [[Food and Drug Administration]] (FDA) | date=13 May 2022 | url=https://www.fda.gov/media/155227/download | format=PDF | access-date=22 January 2023 | archive-date=6 December 2022 | archive-url=https://web.archive.org/web/20221206210020/https://www.fda.gov/media/155227/download | url-status=live }} {{PD-notice}}</ref>
Chemotherapy drugs are designed to kill cancer cells but can damage normal tissues as well.<ref name="FDA PR" /> The bone marrow is particularly susceptible to chemotherapy damage.<ref name="FDA PR" /> The bone marrow makes red blood cells, white blood cells, and platelets (small fragments in the blood) that transport oxygen, fight infection, and stop bleeding.<ref name="FDA PR" /> When damaged, the bone marrow produces fewer of these cells, leading to fatigue, increased risk of infection, and bleeding, among other problems.<ref name="FDA PR" /> Trilaciclib may help protect the normal bone marrow cells from the harmful effects of chemotherapy.<ref name="FDA PR" />
Line 123 ⟶ 116:
== External links ==
* {{ClinicalTrialsGov|NCT03041311|Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC)}}
* {{ClinicalTrialsGov|NCT02499770|Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)}}
* {{ClinicalTrialsGov|NCT02514447|Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy}}
{{Detoxifying agents for antineoplastic treatment}}
{{Portal bar | Medicine}}
[[Category:Protein kinase inhibitors]]
[[Category:Chemotherapeutic adjuvants]]
Line 139 ⟶ 130:
[[Category:Amides]]
[[Category:Guanidines]]
[[Category:CDK inhibitors]]
| |||